US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Krista Davis, Senior Vice President and Chief Human Resources Officer at ANI Pharmaceuticals (NASDAQ:ANIP), a specialty pharmaceutical company with a market capitalization of $1.2 billion and strong revenue growth of 26.2% over the last twelve months, recently sold 1,000 shares of the company’s common stock. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value estimate. The transaction, executed on March 7, 2025, was carried out at a price of $60.86 per share, amounting to a total sale value of $60,860.
Following this sale, Davis retains 66,525 shares in the company. The sale was part of a pre-established Rule 10b5-1 trading plan, which she adopted on August 23, 2024. This plan allows insiders to set up a predetermined schedule for selling stocks, aiming to avoid potential conflicts of interest.
In other recent news, ANI Pharmaceuticals reported fourth-quarter earnings that exceeded analyst expectations, with adjusted earnings per share reaching $1.63 compared to the estimated $1.45. The company also reported revenue of $190.6 million, surpassing the consensus estimate of $175.12 million and marking a 44.8% year-over-year increase. This strong performance led to an upward revision of its 2025 guidance, with expected revenue now between $756 million and $776 million, above the previous forecast and analyst consensus. Leerink Partners responded to these positive developments by raising their price target for ANI Pharmaceuticals to $82, maintaining an Outperform rating, and highlighting the potential growth of Cortrophin Gel and the strategic importance of Iluvien and Yutiq.
The company’s Rare Disease segment was a significant contributor to growth, with revenue more than doubling to $87 million, including $59.4 million from Cortrophin Gel and $27.6 million from Iluvien and Yutiq. Truist Securities maintained a Hold rating with a $62 price target, noting ANI’s strategic consolidation of its Established Brands into the "Rare Disease and Brands" segment as a creative approach to mitigate challenges faced by Iluvien and Yutiq. ANI Pharmaceuticals is also preparing to present data from the New Day and Synchronicity studies related to these products in the second quarter of 2025. The company anticipates launching a pre-filled syringe formulation of Cortrophin Gel in the second quarter of 2025, slightly adjusting the timeline from the initially expected first half of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.